Adjustment of urine PH as effective tool for successful metaphylaxis of urinary stone disease. phytotherapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urinary stone disease constitutes significant burden for healthcare system worldwide. Metaphylaxis after removal or spontaneous passage of urinary stone may be an effective measure for the prevention of recurrent stone episodes. An adjustment of urine pH, based on the type of urinary stone plays a key role in the metaphylaxis of urolithiasis. The use of combined preparations based on herbal plants, which has antioxidant, anti-inflammatory, antimicrobial activity and diuretic effect, and also affects pH level of urine without impairment of the body microbiome, is very promising for the metaphylaxis of urinary stone disease.

Full Text

Restricted Access

About the authors

V. S Saenko

FGAOU VO I.M. Sechenov First Moscow State Medical University

Email: saenkovs@mail.ru
MD, professor, Institute of Uronephrology and Reproductive Health Moscow, Russia

E. L Lachinov

City Clinical Hospital №15

Email: Lachinove@mail.ru
Ph.D., urologist City Clinical Hospital №15

D. A Zhantlisov

City Clinical Hospital №15

Email: Cyclopentan2009@rambler.ru
urologist City Clinical Hospital №15

M. I Gorbachev

City Clinical Hospital № 15

Email: Mikko85@mail.ru
urologist City Clinical Hospital №15

A. A Soltanov

City Clinical Hospital № 15

Email: ArtSoltanov@mail.ru
urologist Moscow, Russia

References

  1. Shoag J., Tasian G.E., Goldfarb D.S., Eisner B.H. The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis 2015; 22: 273-278.
  2. Romero V., Akpinar H., Assimos D.G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 2010; 12: 86-96.
  3. Fisang С., Anding R., Lats S., Laude N. Urolitiasis-an Interdisciplinary Diagnostic, Therapeutic and Secondary Preventive Challenge. Dtsch Arztebl Int. 2015;112:83-91.
  4. Sakhaee K., Maalouf N.M., Sinnott B. Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab. 2012; 97: 1847-1860.
  5. Moe OW. Kidney stones: pathophysiology and medical management. Lancet 2006; 367: 333-344.
  6. Sorokin I., Mamoulakis C., Miyazawa K. et al. Epidemiology of stone disease across the world. World J. Urol. 2017;35(9):1301-1309. doi: 10.1007/s00345-017-2008-6.
  7. Khan S.R. et al. Kidney stones. Nature Reviews Disease Primers. 2016;2:1-22. https://doi.org/10.1038/nrdp.2016.8
  8. Schwaderer A.L., Wolfe A.J. The association between bacteria and urinary stones. Ann Transl Med. 2017;5:32. https://doi.org/10.21037/atm.2016.11.73 (2017)
  9. Sokol E., Nigmatulina E., Maksimova N., Chiglintsev A. CaC2O4 H2O spherulites in human kidney stones: morphology, chemical composition, and growth regime. European Journal of Mineralogy. 2005;17:285-229.
  10. Scales C.D., Jr., Smith A.C., Hanley J.M., Saigal C.S. Prevalence of kidney stones in the United States. European urology. 2012;62(1):160-165.
  11. Goldfarb D.S., Avery A.R., Beara-Lasic L., Duncan G.E., Goldberg J. A Twin Study of Genetic Influences on Nephrolithiasis in Women and Men. Kidney International Reports.2019;4:535-540.
  12. Del Valle E.E., Negri A.L., Spivacow F.R., Rosende G., Forrester M., Pinduli I. Metabolic diagnosis in Stone formers in relation to body mass index. Urol Res 2012;40:47-52.
  13. Ping H., Lu N., Wang M., Lu J., Liu Y., Qiao L., Wang Y., Jiang L., Zhang X. New-onset metabolic risk factors and the incidence of kidney stones: a prospective cohort study.BJU Int. 2019. doi: 10.1111/bju.14805/
  14. Brown C.M., Ackermann D.K., Purich D.L. EQUIL93: a tool for experimental and clinical urolithiasis. Urol. Res. 1994;22:119-126.
  15. Robertson W.G., Peacock M. Nordin B.E. Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin. Sci. 1971;40:365-374.
  16. Stoller V.L., Meng M.V., Abrahams H.M., Kane J.P. The primary stone event; a new hypothesis involving a vascular etiology. J Urol 2004;171:1920-1924.
  17. Robertson W.G. Potential role of fluctuations in the composition of renal tubular fluid through the nephron in the initiation of Randall’s plugs and calcium oxalate crystalluria in a computer model of renal function. Urolithiasis 2015;43(Suppl. 1):93-107.
  18. Glybochko P.V., Svistunov A.A., Rossolovski A.N., Ponukalin A.N., Zakharova N.B., Bliumberg B.I., Berezinets O.L. Endothelial dysfunction in urolithiasis patients. Urologiia. 2010;(3):3-6.
  19. Rao C.Y., Sun X.Y., Ouyang J.M. Effects of physical properties of nano-sized hydroxyapatite crystals on cellular toxicity in renal epithelial cells. Mater Sci Eng C Mater Biol Appl. 2019;103:109807. doi: 10.1016/j.msec.2019.109807.
  20. Edwards A., Layton A.T. Modulation of outer medullary NaCl transport and oxygenation by nitric oxide and superoxide. Am J Physiol Renal Physiol. 2011; 301:F979.
  21. Пытель Ю.А., Борисов В.В., Симонов В.А. Физиология человека. Мочевые пути. Москва. Высшая школа. 1986;99.
  22. Robertson W.G. Potential role of fluctuations in the composition of renal tubular fluid through the nephron in the initiation of Randall’s plugs and calcium oxalate crystalluria in a computer model of renal function. Urolithiasis. 2015;43(Suppl. 1):93-107.
  23. Wollin D.A., Kaplan A.G., Preminger G.M., Ferraro P.M., Nouvenne A., Tasca A., Croppi E., Gambaro G., Heilberg I.P. Defining metabolic activity of nephrolithiasis Appropriate evaluation and follow-up of stone formers. AJUR 231_proof 2 July 2018;3/8, https://doi.org/10.1016/j.ajur.2018.06.007
  24. Вощула В.И. Мочекаменная болезнь. Этиотропное и патогенетическое лечение, профилактика. Минск; 2007. 268 с.
  25. Nephrology. Guide for doctors/edited by Tareeva I. E. M., Medicine. 2000. 688 s. Russain (Нефрология. Руководство для врачей/под редакцией Тареевой И.Е. М., Медицина. 2000. 688 с.).
  26. Worcester E.M., Bergsland K.J., Gillen D.L., Coe F.L. Mechanism for higher urine pH in normal women compared with men. Am J Physiol Renal Physiol. 2018;314: F623-F629.
  27. Menezes C.J., Worcester E.M., Coe F.L., Asplin J., Bergsland K.J., Ko B. Mechanisms for falling urine pH with age in stone formers. Am J Physiol Renal Physiol. 20191;317(7):F65-F72. doi: 10.1152/ajprenal.00066.2019.
  28. Daudon M., Dore J.C., Jungers P., Lacour B. Changes in stone composition according to age and gender of patients: a multi ariate epidemiological approach. Urol Res 2004;2:241-247.
  29. Lieske J.C., Rule A.D., Krambeck A.E., Williams J.C., Bergstralh E.J., Mehta R.A., Moyer T.P. Stone composition as a function of age and sex. Clin J Am Soc Nephrol. 2014; 9:2141-2146.
  30. Carbone A, Al S.Y., Tasca A., Palleschi G., Fuschi A., De N.C., Bozzini G., Mazzaferro S., Pastore A.L. Obesity and kidney stone disease: a systematic review. Minerva Urol Nefrol 2018;70: 393-400.
  31. Li W.M., Chou Y.H., Li C.C., Liu C.C.,Huang S.P., Wu W.J., Chen C.W.,Su C.Y., Lee M.H., Wei Y.C., Huang C.H. Association of body mass index and urine pH in patients with urolithiasis. Urol Res 2009;37:551:193-196.
  32. Poggio E.D., Rule A.D., Tanchanco R., Arrigain S., Butler R.S., Srinivas T., Stephany B.R., Meyer K.H., Nurko S., Fatica R.A., Shoskes D.A., Krishnamurthi V., Goldfarb D.A., Gill I., Schreiber M.J. Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int 2009;75:1079-1087.
  33. Relman A.S., Lennon E.J., Lemann J., Jr. Endogenous production of fixed acid and the measurement of the net balance of acid in normal subjects. J Clin Invest 1961;40: 1621-1630.
  34. Juthatip Manissorn, Kedsarin Fongngern, Paleerath Peerapen & Visith Thongboonkerd. Systematic evaluation for effects of urine pH on calcium oxalate crystallization, crystal-cell adhesion and internalization into renal tubular cells. Scientific Reports 1798. doi: 10.1038/s41598-017-01953-4/
  35. Bamberger J.N., Blum K.A.,Kan K.M., Parkhomenko E., GallanteB., Gupta M. Clinical and Metabolic Correlates of Calcium Oxalate Stone Subtypes: Implications for Etiology and Management. J Endourol. 2019 https://doi. org/10.1089/end.2019.0245
  36. Lightwood R. Calcium Infarction of the kidneys in infants. Arch Dis Child 1935;10:205-206.
  37. Albright F., Burnett C.H., Parson W., Reifenstein ECRA. Osteomalacia and late rickets. Medicine 1946;25(4):339-479.
  38. Pines K.L., Gilbert H. Renal tubular acidosis with osteomalacia. Am J Med 1951;11(3):302-331.
  39. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 2002;13(8):2160-2170.
  40. Hesse A., Heimbach D. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol 1999;17(5):308-315.
  41. Romero V., Akpinar H., Assimos D.G. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010;12(2-3):86-96.
  42. Griffith D.P., Osborne C.A. Infection (urease) stones. Min Electrolyte Metab. 1987;13:278-285.
  43. Bichler K.H., Eipper E., Naber K. et al. Urinary infection stones. Int J Antimicrob Agents. 2002; 19:488-498.
  44. Hugosson J., Grenabo L., Hedelin H. et al. Bacteriology of upper urinary tract stones. J Urol. 1990;143:965-968.
  45. Segura J.W., Erickson S.B., Wilson D.M., et al. Infected renal lithiasis: results of long-term surgical and medical management. In: Smith L.H., Robertson W.G., Finlayson B. (eds): Urolithiasis: Clinical and Basic Research. New York: Plenum Press. 1981. Р. 195-198.
  46. Константинова О.В., Дзеранов Н.К., Лавринова Л.Н., Деревянко Н.Н., Голованов С.А., Новодворская И.К. Бактериурия при различных формах мочекаменной болезни. Х Российский национальный конгресс «Человек и лекарство». Тезисы докладов. М., 2003. C. 224.
  47. Константинова О.В., Катибов М.И., Яненко Э.К. Инфекционно-воспалительный процесс в почках как один из факторов риска образования коралловидных камней. тезисы докл. Материалы XV Конгресса Российского общества урологов «Урология в XXI веке». СПб., 2015. С. 157.
  48. Mariappan P., Smith G., Bariol S.V., et al. Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. J Urol. 2005;173:1610-1614.
  49. Hedelin H., Brorson J., Grenabo L., Pettersson S. Ureaplasm urealitycum and upper urinary tract stones. Brit J Urol. 1984;56:244-249.
  50. Cicerello E., Mangano M., Cova G.D., Merlo F., Maccatrozzo L. Metabolic evaluation in patients with infected nephrolithiasis: Is it necessary? Arch Ital Urol Androl. 2016;88(3):208-211. doi: 10.4081/aiua.2016.3.208.
  51. Hesse A., Bongartz D., Struwe F., Schoeneich G. Senkung des Risikos der Phosphatsteinbildung durch L-Methionin. Urologe [B] 1997;37:489-492.
  52. Hess B, Ackermann D. Preventive measures in stones. due to infection, uric acid and cystine. Ther Umsch 1992;49:44-48.
  53. Jarrar K, Boedeker R.H., Weidner W. Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris) 1996;30:112-117.
  54. Murphy F.J., Zelman S., Mau W. Ascorbic Acid as a urinary acidifying agent. 2. Its adjunctive role in chronic urinary infection. J Urol. 1965;94:300-303.
  55. Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. A. Hesse a D. Heimbach. World J Urol. 1999;17:308-315.
  56. Noureldin Y.A., da Silva A., Fahmy N, Andonian S. Is it safe to prescribe ascorbic acid for urinary acidification in stone-forming patients with alkaline urine? Turk J Urol 2017;43(2): 183-188. doi: 10.5152/tud.2017.02700
  57. Fishbein W.N. Carbone P.P. Urease Catalysis: II. Inhibition of the enzyme by hydroxyurea, hydroxylamine, and acetohydroxamic acid. J Biol Chem 1965;240:2407-414.
  58. Barros M.E., Lima R, Mercuri L.P., Matos J.R., Schor N, Biom M.A. Effect of extract of P. niruri on crystal deposition in experimental urolithiasis. Urol Res. 2006;34(6):351-337.
  59. Gupta A., Chaphalkar S.R. Anti-inflammatory and immunosuppressive activities of some flavonoids from medicinal plants. J HerbMed Pharmacol. 2016;5:120-124.
  60. Carrera-Quintanar L., Lopez Roa R.I., Quintero-Fabian S., Sanchez-Sanchez M.A., Vizmanos B., Ortuno-Sahagun D. Phytochemicals That Influence Gut Microbiota as Prophylactics and for the Treatment of Obesity and Inflammatory Diseases. Mediators Inflamm. 2018;26;2018:9734845. Boi: 10.1155/2018/9734845.
  61. Koo K, Aro T, Matlaga B.R. Buyer Beware: Evidence-Based Evaluation of Dietary Supplements for Nephrolithiasis. Journal of Endourology Ahead of Print normal Published Online: 24 Mar 2020. https://doi.org/10.1089/ end.2019.0828
  62. Маньшина Н.В. Курортология для всех. За здоровьем на курорт. Минск, Вече, 2007. С. 153-157.
  63. Ардашникова С.Н., Апрдашников М.С., Беленький Л.С. и др. Общая курортотерапия. Медгиз, 1959.
  64. Ahmed S, Hasan M.M., Khan H, Mahmood Z.A., Patel S. The mechanistic insight of polyphenols in calcium oxalate urolithiasis mitigation. Biomed Pharmacother. 2018;106:1292-1299. doi: 10.1016/j.biopha.2018.07.080.
  65. Kebler T, Jansen B, Hesse A. Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation. European Journal of Clinical Nutrition. 2002;56:1020-1023. Doi:10.1038/ sj.ejcn.1601442.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies